Annual EBITDA
-$72.09 M
-$15.69 M-27.81%
September 30, 2024
Summary
- As of February 7, 2025, OTLK annual EBITDA is -$72.09 million, with the most recent change of -$15.69 million (-27.81%) on September 30, 2024.
- During the last 3 years, OTLK annual EBITDA has fallen by -$20.13 million (-38.74%).
- OTLK annual EBITDA is now -526.14% below its all-time high of -$11.51 million, reached on September 30, 2014.
Performance
OTLK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$5.72 M
-$38.72 M-87.13%
September 1, 2024
Summary
- As of February 7, 2025, OTLK quarterly EBITDA is $5.72 million, with the most recent change of -$38.72 million (-87.13%) on September 1, 2024.
- Over the past year, OTLK quarterly EBITDA has increased by +$16.02 million (+155.56%).
- OTLK quarterly EBITDA is now -87.13% below its all-time high of $44.44 million, reached on June 30, 2024.
Performance
OTLK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$20.95 M
+$18.70 M+830.38%
September 1, 2024
Summary
- As of February 7, 2025, OTLK TTM EBITDA is $20.95 million, with the most recent change of +$18.70 million (+830.38%) on September 1, 2024.
- Over the past year, OTLK TTM EBITDA has increased by +$71.72 million (+141.27%).
- OTLK TTM EBITDA is now at all-time high.
Performance
OTLK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
OTLK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.8% | +155.6% | +141.3% |
| 3 y3 years | -38.7% | +143.7% | +140.3% |
| 5 y5 years | -131.8% | +218.5% | +158.9% |
OTLK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.7% | at low | -87.1% | +127.7% | at high | +131.3% |
| 5 y | 5-year | -131.8% | at low | -87.1% | +127.7% | at high | +131.3% |
| alltime | all time | -526.1% | at low | -87.1% | +126.7% | at high | +131.3% |
Outlook Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$72.09 M(+27.8%) | - | - |
| Sep 2024 | - | $5.72 M(-87.1%) | $20.95 M(+830.4%) |
| Jun 2024 | - | $44.44 M(-335.0%) | $2.25 M(-103.6%) |
| Mar 2024 | - | -$18.91 M(+83.7%) | -$62.85 M(+23.8%) |
| Dec 2023 | - | -$10.29 M(-20.7%) | -$50.76 M(-9.6%) |
| Sep 2023 | -$56.40 M(-12.4%) | -$12.98 M(-37.2%) | -$56.15 M(-4.2%) |
| Jun 2023 | - | -$20.66 M(+202.7%) | -$58.60 M(+6.7%) |
| Mar 2023 | - | -$6.83 M(-56.5%) | -$54.90 M(-18.0%) |
| Dec 2022 | - | -$15.68 M(+1.6%) | -$66.94 M(+2.5%) |
| Sep 2022 | -$64.36 M(+23.9%) | -$15.43 M(-9.1%) | -$65.32 M(+3.7%) |
| Jun 2022 | - | -$16.97 M(-10.0%) | -$62.98 M(+8.8%) |
| Mar 2022 | - | -$18.86 M(+34.1%) | -$57.89 M(+11.7%) |
| Dec 2021 | - | -$14.06 M(+7.5%) | -$51.81 M(-0.3%) |
| Sep 2021 | -$51.96 M(+43.5%) | -$13.08 M(+10.0%) | -$51.96 M(+6.7%) |
| Jun 2021 | - | -$11.89 M(-6.9%) | -$48.70 M(+14.5%) |
| Mar 2021 | - | -$12.77 M(-10.2%) | -$42.53 M(+23.0%) |
| Dec 2020 | - | -$14.22 M(+44.7%) | -$34.59 M(-4.5%) |
| Sep 2020 | -$36.20 M(+16.4%) | -$9.82 M(+71.7%) | -$36.20 M(-4.8%) |
| Jun 2020 | - | -$5.72 M(+18.5%) | -$38.01 M(+6.8%) |
| Mar 2020 | - | -$4.83 M(-69.5%) | -$35.59 M(-9.1%) |
| Dec 2019 | - | -$15.83 M(+36.1%) | -$39.14 M(+25.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | -$31.11 M(+16.1%) | -$11.63 M(+252.1%) | -$31.11 M(+2.9%) |
| Jun 2019 | - | -$3.30 M(-60.6%) | -$30.24 M(-9.5%) |
| Mar 2019 | - | -$8.37 M(+7.4%) | -$33.40 M(+8.0%) |
| Dec 2018 | - | -$7.80 M(-27.6%) | -$30.92 M(+15.4%) |
| Sep 2018 | -$26.79 M(-10.8%) | -$10.77 M(+66.6%) | -$26.79 M(+40.4%) |
| Jun 2018 | - | -$6.46 M(+9.8%) | -$19.09 M(+22.8%) |
| Mar 2018 | - | -$5.89 M(+60.1%) | -$15.54 M(-1.5%) |
| Dec 2017 | - | -$3.68 M(+20.2%) | -$15.77 M(-47.5%) |
| Sep 2017 | -$30.03 M(-38.7%) | -$3.06 M(+5.0%) | -$30.03 M(-17.3%) |
| Jun 2017 | - | -$2.91 M(-52.4%) | -$36.32 M(-33.8%) |
| Mar 2017 | - | -$6.12 M(-65.9%) | -$54.84 M(+7.4%) |
| Dec 2016 | - | -$17.94 M(+91.8%) | -$51.07 M(+4.3%) |
| Sep 2016 | -$48.95 M(+9.4%) | -$9.35 M(-56.4%) | -$48.95 M(-12.6%) |
| Jun 2016 | - | -$21.43 M(+809.6%) | -$56.01 M(+23.9%) |
| Mar 2016 | - | -$2.36 M(-85.1%) | -$45.21 M(-20.2%) |
| Dec 2015 | - | -$15.82 M(-3.6%) | -$56.64 M(+26.6%) |
| Sep 2015 | -$44.74 M(+288.6%) | -$16.41 M(+54.4%) | -$44.74 M(+57.9%) |
| Jun 2015 | - | -$10.62 M(-22.9%) | -$28.33 M(+60.0%) |
| Mar 2015 | - | -$13.78 M(+251.5%) | -$17.70 M(+351.5%) |
| Dec 2014 | - | -$3.92 M | -$3.92 M |
| Sep 2014 | -$11.51 M | - | - |
FAQ
- What is Outlook Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics annual EBITDA year-on-year change?
- What is Outlook Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly EBITDA year-on-year change?
- What is Outlook Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics TTM EBITDA year-on-year change?
What is Outlook Therapeutics annual EBITDA?
The current annual EBITDA of OTLK is -$72.09 M
What is the all time high annual EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high annual EBITDA is -$11.51 M
What is Outlook Therapeutics annual EBITDA year-on-year change?
Over the past year, OTLK annual EBITDA has changed by -$15.69 M (-27.81%)
What is Outlook Therapeutics quarterly EBITDA?
The current quarterly EBITDA of OTLK is $5.72 M
What is the all time high quarterly EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly EBITDA is $44.44 M
What is Outlook Therapeutics quarterly EBITDA year-on-year change?
Over the past year, OTLK quarterly EBITDA has changed by +$16.02 M (+155.56%)
What is Outlook Therapeutics TTM EBITDA?
The current TTM EBITDA of OTLK is $20.95 M
What is the all time high TTM EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM EBITDA is $20.95 M
What is Outlook Therapeutics TTM EBITDA year-on-year change?
Over the past year, OTLK TTM EBITDA has changed by +$71.72 M (+141.27%)